HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J’s Consumer Health Product Sales Slump In Comparison A Year After COVID-19 Stockpiling

Executive Summary

Worldwide consumer health sales in January-March period were down 3.3% to $3.5bn with results off 7.4% to $1.6bn in the US and up 0.5% to $1.9bn internationally. However, excluding “COVID-19 comparison” in the year-ago period, the consumer health segment grew low-single-digits.

You may also be interested in...



J&J Sees Clear But Bumpy Road Ahead For Consumer Health, Personal Care Business Growth

Q1 results arrive with cautionary forecasts on “external challenges” limiting sales and net income growth. Limited availability and higher commodity prices and increased costs for labor, energy and transportation are “pervasive across the enterprise but most notable in consumer health,” says CFO Joseph Wolk.

US Q2 Consumer Health Earnings Preview: Will More Favorable Year-Ago Comparisons Help?

April-June sales of OTC drugs, supplements and personal care products likely will show at least notable and potentially strong increases from year-ago period when consumers slowed spending after splurging during 2020 Q1 as novel coronavirus pandemic sent shockwaves through the marketplace.

J&J Consumer Health More Than A Revenue Stream: Driving Development Across Segments

CEO Alex Gorsky and medtech business leader Joaquin Duato say consumers’ growing interest in self-care is influencing the firm’s work across segments. Consumer health also is driver for Healthy Lives Mission to invest $800m through 2030 to improve the health of people and the world.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS151246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel